• 1. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 2. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Prostaglandins and related compounds
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Eicosanoids Prostaglandins and related compounds

Recent Advances in 15(R)-Prostaglandin E2 (CAS 38873-82-4) Research: Implications for Biomedical Applications

15(R)-Prostaglandin E2 (15(R)-PGE2, CAS 38873-82-4), a stereoisomer of the well-studied prostaglandin E2 (PGE2), has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. Unlike its more common counterpart, 15(S)-PGE2, the 15(R) configuration exhibits unique biological activities, particularly in modulating inflammatory responses, tissue repair, and cellular signaling pathways. This research brief synthesizes the latest findings on 15(R)-PGE2, highlighting its molecular mechanisms, therapeutic potential, and recent advancements in synthesis and application.

Recent studies have elucidated the distinct binding affinities and downstream effects of 15(R)-PGE2 on prostaglandin receptors (EP1-EP4). A 2023 study published in Nature Chemical Biology demonstrated that 15(R)-PGE2 preferentially activates the EP2 receptor, leading to enhanced cAMP signaling and anti-inflammatory effects in murine models of colitis. This receptor specificity contrasts with 15(S)-PGE2, which shows broader receptor activation. The differential signaling underscores the potential for 15(R)-PGE2 as a targeted therapeutic agent in inflammatory diseases.

Advances in synthetic chemistry have enabled more efficient production of 15(R)-PGE2, addressing previous challenges in stereoselective synthesis. A breakthrough reported in Journal of Medicinal Chemistry (2024) described a novel enzymatic cascade using engineered cyclooxygenase-2 (COX-2) mutants to achieve >90% enantiomeric excess for 15(R)-PGE2. This method, leveraging the CAS 38873-82-4 scaffold, significantly improves yield compared to traditional chemical synthesis routes, facilitating larger-scale biomedical studies.

The therapeutic applications of 15(R)-PGE2 are expanding beyond inflammation modulation. Preclinical data presented at the 2024 American Chemical Society meeting revealed its neuroprotective effects in ischemic stroke models, where it reduced infarct volume by 40% via EP4 receptor-mediated blood-brain barrier stabilization. Concurrently, oncology research has identified 15(R)-PGE2 as a modulator of tumor-associated macrophages, polarizing them toward an anti-tumor phenotype in triple-negative breast cancer models.

Despite these promising developments, challenges remain in clinical translation. Pharmacokinetic studies indicate rapid metabolism of 15(R)-PGE2 in vivo, with a plasma half-life of <15 minutes in primates. Recent work published in ACS Pharmacology & Translational Science (2024) explores prodrug strategies using CAS 38873-82-4 derivatives to improve stability, with methyl ester modifications showing 3-fold increased bioavailability in Phase I trials.

The growing body of research positions 15(R)-Prostaglandin E2 as a multifaceted bioactive molecule with applications ranging from anti-inflammatory therapies to neuroprotection and cancer immunotherapy. As synthetic methods evolve and receptor-specific effects become better characterized, this compound represents a compelling case study in stereochemistry-driven biological activity. Future directions include structure-activity relationship studies of CAS 38873-82-4 analogs and combination therapies leveraging its unique signaling profile.

• 363-24-6(Prostaglandin E2)
• 27415-25-4(8-Isoprostaglandin E2)
• 21003-46-3(8-Isoprostaglandin E1)
• 745-65-3(Prostaglandin E1)
• 24570-01-2(11-Epiprostaglandin E1)
• 112137-89-0(misoprostol acid)
• 38310-90-6(Prosta-5,13-dien-1-oicacid, 11,15-dihydroxy-9-oxo-, (5Z,11b,13E,15S)- (9CI))
• 36150-00-2(5-trans-Prostaglandin E2)
• 17968-82-0(Prostaglandin D1)
• 119008-22-9(5,6-DIHYDRO PGE3)